New research examining treatment initiation patterns among patients with axial spondyloarthritis revealed significant sex-based disparities, shedding light on the process from diagnosis to therapeutic intervention.
New research examining treatment initiation patterns among patients with axial spondyloarthritis (axSpA) has revealed significant sex-based disparities, shedding light on the process from diagnosis to therapeutic intervention. Although nonsteroidal anti-inflammatory drug (NSAID) usage predominated among patients with newly diagnosed axSpA compared with biologic disease-modifying antirheumatic drugs (bDMARDs), a closer look showed differences in treatment initiation timelines between male and female individuals, according to the findings published in Arthritis Care & Research.
Data from the IBM MarketScan Database spanning from 2013 to 2018 were utilized for the study, which aimed to evaluate sex differences in the time to initiation of NSAIDs or bDMARDs among patients with axSpA.
A total of 174,632 adult patients diagnosed with the rheumatic condition were included in the analysis. The time between axSpA diagnosis and the initiation of NSAIDs or bDMARDs was assessed. Adjusted HRs (aHRs) were calculated using survival analyses, and Cox proportional hazard models were employed to determine associations between sex and treatment initiation predictors.
Results showed that the average age at axSpA diagnosis was 48.2 years, with a female majority (65.7%) . Before diagnosis, 37.8% of patients had received at least 1 NSAID prescription. When analyzing those without at least 2 different prescription NSAIDs before diagnosis, women (32.9%) initiated NSAIDs earlier than men (29.3%; aHR, 1.14; 95% CI, 1.11-1.16).
For patients with a history of NSAID use (with ≥2 different prescription NSAID dispensations in the baseline period), 4.2% initiated bDMARDs while 77.9% continued NSAID therapy post diagnosis. The time to bDMARD initiation was longer for women compared with men (aHR, 0.61; 95% CI, 0.52-0.72), although bDMARD initiation was quicker among those with baseline NSAID use.
Throughout the baseline period, indicators of health care utilization revealed trends, according to the study. While the majority of patients had primary care physician visits, a smaller percentage had visited a rheumatologist, indicating potential delays in accessing specialized care. Furthermore, a significant proportion of patients had utilized urgent care or emergency department services, and a notable minority of patients had been prescribed DMARDs or opioids during this period, suggesting varied approaches to managing axSpA symptoms and disease progression.
“The decision to initiate a bDMARD in axSpA is complex for patients, physicians, and payers because of the high cost of these medications, as well as the requirement by many payers for prior authorization,” the researchers concluded. “In our study, females appeared more likely to continue NSAIDs use, and the time to initiate bDMARDs was longer for females than males. This emphasizes the need for additional research to determine whether low initiation rates of bDMARDs after treatment with 2 different prescription NSAIDs among females with a diagnosis of axSpA, compared to that among males, represents a missed opportunity to prevent disease progression and improve quality of life for this patient population.”
Reference
Shridharmurthy D, Lapane KL, Baek J, et al. Sex differences in time to initiate NSAIDs or bDMARDs among patients with axial spondyloarthritis. Arthritis Care Res (Hoboken). Published online March 27, 2024. doi:10.1002/acr.25332
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Health Equity and Access Weekly Roundup: April 27, 2024
April 27th 2024Racial disparities in end-of-life care, the role of wellness and faith in minority health, award-winning research on health disparities, societal factors impacting cardiometabolic health, and rising mental health challenges among US youth are all covered this week in the Center on Health Equity and Access.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More